Brain Cancer

ASTRO Offers Guidance on RT for IDH-Mutant Diffuse Grade 2, 3 Glioma

Publish Date September 26, 2022

Guideline recommendations support reduction in volume of brain irradiation while attempting to maximize disease control.

Emopamil-Binding Protein Inhibitor Designated Orphan Drug for Brain Cancer

By

Brian Park, PharmD

Publish Date July 22, 2022

DSP-0390 is an inhibitor of emopamil-binding protein, an endoplasmic reticulum membrane protein involved in cholesterol biosynthesis.

High-Dose Methotrexate and Nephrotoxicity Risk in Patients With Hematologic Cancers

By

Jennifer Larson

Publish Date June 28, 2022

The retrospective analysis included 144 patients in three Australian health care facilities with a total of 539 episodes of high-dose methotrexate.

Late Outcomes Support Radiation-Limiting Treatment Strategies for Pediatric Glioma

By

Jessica Nye, PhD

Publish Date June 23, 2022

Use of radiation decreased over time, while use of surgery alone increased.

Survivors of Medulloblastoma Have Greater Risk of Stroke, Severe Hearing Loss

By

Jonathan Goodman, MPhil

Publish Date June 22, 2022

Medulloblastoma survivors had an increased risk of long-term adverse outcomes.

Brain Cancer Clinical Trials

Analysis of Sacituzumab Govitecan Shows Manageable Safety Profile in mTNBC

Researchers report on the safety data from the phase 3 ASCENT trial of sacituzumab govitecan in the treatment of metastatic triple-negative breast cancer.

Besremi Approved for Adults With Polycythemia Vera

Besremi is a monopegylated, long-acting interferon, which exhibits its cellular effects in the bone marrow in polycythemia vera.

Trabectedin Improves PFS in Advanced Leiomyosarcoma

Adding trabectedin to doxorubicin doubled the median progression-free survival.

Race, Ethnicity Underreported in Early Phase Pediatric Cancer Trials

Race and ethnicity were reported in less than 25% of the trials studied.

Larotrectinib Produces “Remarkable” Responses in NTRK Fusion-Positive CNS Tumors

The median duration of response was not reached at a median follow-up of 26 months.